# PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis

> **NCT04783727** · NA · TERMINATED · sponsor: **Research Center Borstel** · enrollment: 4 (actual)

## Conditions studied

- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Bacterial Infections
- Mycobacterial Infection

## Interventions

- **DIAGNOSTIC_TEST:** Individualised treatment duration based on RNA transcriptomic model

## Key facts

- **NCT ID:** NCT04783727
- **Lead sponsor:** Research Center Borstel
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Change in WHO recommendations for standard of care (control arm); availability of new shorter treatment regimens for MDR-TB; war in Ukraine where two study sites are located; key trial team members left the team.
- **Last updated:** 2023-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04783727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04783727, "PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04783727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*